HomeAI · summaries
Storia in 2 fonti
Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal Manchanda
India's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and consumer healthcare. While US FDA approvals for complex generics remain a challenge, innovation and contract manufacturing offer significant future profit pools. Experts anticipate biosimilars could generate substantial revenue, and despite a slow start, GLP-1 drugs show long-term promise. Sun Pharma is highlighted as a preferred domestic investment.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
economictimes.indiatimes.com
Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal Manchanda
India's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and consumer healthcare. While US FDA…
- ·
thehindubusinessline.com
India pharma sector shifts focus to biosimilars, biologics and high-value growth
India pharma sector moves beyond generics to biosimilars, biologics and AI-driven manufacturing, strengthening exports and global competitiveness.